IntelGenx Corp. Pitch Deck (2016): 17-Slide Breakdown

IntelGenx Corp. (IGX) positions itself as a specialized drug delivery company focusing on oral thin films (VersaFilm) and controlled-release tablets (VersaTab). The deck emphasizes a low-risk R&D model by improving already-approved drugs to enhance patient compliance and absorption. With a stated $19B TAM and a robust pipeline targeting high-value indications like Migraine ($2B) and Schizophrenia ($5.2B), the company demonstrates significant commercial potential. Notably, the presentation highlights a strategic shift toward in-house manufacturing to capture higher margins and provide 'one-sto…

Key takeaways

• The company targets a combined $19B Total Addressable Market (TAM) across its two core technology platforms, VersaFilm and VersaTab (Slide 4).
• IntelGenx utilizes a 're-formulation' strategy, aiming to make approved drugs better rather than developing new chemical entities from scratch (Slide 1).
• CEO Horst G. Zerbe brings significant credibility as the co-developer of the original Listerine breath strips, the commercial benchmark for oral thin films (Slide 2).
• The VersaFilm platform alone targets four major indications with a combined market opportunity of $13.1B, including Schizophrenia and Erectile Dysfunction (Slide 6).
• The product pipeline is highly diversified, with 14 distinct programs ranging from formulation development to full commercial launch (Slide 8).
• Strategic transition to in-house manufacturing (Blending, Coating, Packaging) is designed to reduce dependence on external partners and increase R&D capabilities (Slide 10).
• Revenue growth is accelerating, with nine-month totals for 2015 reaching $3.59M, a 332% increase over the same period in 2014 (Slide 12).
• The team is highly technical, consisting of 18 employees, 8 of whom hold Ph.D. degrees (Slide 14).

Frequently asked questions

What is the core technology offered by IntelGenx?

IntelGenx focuses on two proprietary delivery platforms: VersaFilm, an oral thin film technology, and VersaTab, a multilayer controlled-release tablet technology. VersaFilm is designed for rapid disintegration and improved absorption without the need for water, while VersaTab allows for complex release profiles of active ingredients.

How does IntelGenx mitigate the risks associated with drug development?

The company follows a strategy of 'making approved drugs better.' By applying their delivery technologies to existing, FDA-approved compounds, they bypass the high failure rates associated with discovering new molecules, focusing instead on bioequivalence and improved patient outcomes.

What are the primary market opportunities for their thin film technology?

According to Slide 6, the VersaFilm platform targets four primary areas: Schizophrenia ($5.2B), Erectile Dysfunction ($4.2B), Migraine ($2B), and Opioid Dependence ($1.7B). Their Rizaport product for Migraines has already achieved its first European marketing approval.

Why is the company moving manufacturing in-house?

As detailed on Slide 10, in-house manufacturing allows IntelGenx to integrate pharmaceutical services with IP protection, reduce reliance on third-party partners, and offer clients a 'one-stop shop' experience. This vertical integration is intended to increase overall profitability and R&D speed.

What does the financial trajectory look like for the company in this deck?

The deck shows a significant upward trend in revenue. Slide 12 reports that Q3 2015 revenue was $2.38M, nearly five times the $0.45M reported in Q3 2014. The nine-month revenue for 2015 ($3.59M) also vastly outperformed the full nine months of 2014 ($0.83M).

IntelGenx Corp. pitch deck: the facts

Company

IntelGenx Corp.

Year

2016

Stage

Publicly Traded (TSX-V / OTCQX)

Slides

17

Sector

Pharmaceuticals / Drug Delivery

Deck type

Investor Presentation

Outcome

Active (as of deck date)

Headquarters

Saint-Laurent, Quebec, Canada

IntelGenx Corp. pitch deck PDF

The full IntelGenx Corp. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the IntelGenx Corp. pitch deck was used for

This deck is a January 2016 IntelGenx Corp. investor presentation for a publicly traded Canadian pharmaceutical company listed on the TSX-V (IGX) and OTCQX (IGXT). It showcases IntelGenx’s oral drug delivery platforms VersaFilm, VersaTab and AdVersa, positioning them around the theme of “making approved drugs better” via oral thin films and advanced tablets. The presentation emphasizes a $19B total addressable market across migraine, opioid dependence, erectile dysfunction and schizophrenia, along with commercialization of Forfivo XL and European approval of RIZAPORT. While the deck clearly supports ongoing investor relations and highlights capex for in-house manufacturing, no specific equity raise, target amount or valuation directly tied to this exact January 2016 deck could be verified from external financing announcements or filings.

Business model: IntelGenx is a pharmaceutical company focused on developing and manufacturing oral drug delivery systems, particularly oral thin film (VersaFilm), multilayer tablet (VersaTab), and mucoadhesive tablet (AdVersa) technologies for reformulating approved drugs and co-developing products with partners.

Industry

Pharmaceuticals / Drug Delivery.

Round: Public markets / ongoing public company financing; no single discrete private round tied specifically to the January 2016 deck was identified in public disclosures.

Headquarters: Ville St-Laurent, Quebec, Canada (corporate address at 6425 Abrams reported in SEC filings).

Use of funds as presented: Proceeds from a December 2013 registered public offering (gross approximately $3.5 million, net about $3.0 million) were designated for capital investments in VersaFilm manufacturing equipment, leasehold improvements on a new facility, working capital and other general corporate purposes. Debt financing via a BMO Bank of Montreal credit facility (up to CAD$3.5 million) and a CAD$1 million loan fro

What happened after the IntelGenx Corp. deck

Following the 2016 investor deck, IntelGenx continued to advance its oral thin film and tablet platforms, secured regional commercialization deals for RIZAPORT, operated its in-house manufacturing facility financed through government-supported credit, and maintained its status as a public company, leveraging both equity and debt financing rather than a single identifiable private round linked to t

• Launch of Forfivo XL in the U.S. in October 2012 under a licensing partnership with Edgemont Pharmaceuticals, generating
• European marketing approval for RIZAPORT, an oral thin film rizatriptan product for acute migraine, achieved in November
• Signing of a definitive agreement in 2016 with Grupo Juste (now Exeltis) for commercialization of RIZAPORT in Spain and
• Construction of new manufacturing facilities, laboratories and offices at 6420 Abrams, St-Laurent, Quebec, financed via
• A December 2013 registered public offering that raised gross proceeds of approximately $3.5 million, with net proceeds o

What the IntelGenx Corp. deck got right

• Strong, patient-centric positioning of oral thin film and tablet technologies. The deck clearly articulates IntelGenx’s unique value proposition around oral thin films and advanced tablets, emphasizing patient benefits such as rapid disintegration without water, faster onset of action and improved compliance for elderly and pediatric patients or those with swallowing difficulties.[provided_text]
• Clear linkage of platform technologies to large therapeutic markets. By presenting a $19B total addressable market and explicitly linking VersaFilm to major indications like opioid dependence, migraine, erectile dysfunction and schizophrenia, the deck shows that IntelGenx’s platforms target large, established markets rather than niche applications.[provided_text]
• Evidence of existing commercial traction via Forfivo XL and improved financials. The inclusion of a marketed product, Forfivo XL, with noted net sales growth and record Q3 2015 revenue and profitability provides investors with evidence of existing commercial traction and royalty-generating assets, not just pipeline promises.[provided_text]
• Regulatory and partnership validation through RIZAPORT approval. Highlighting the first European marketing approval of RIZAPORT and its use of VersaFilm technology demonstrates regulatory validation of IntelGenx’s core platform and showcases collaboration with partners such as RedHill Biopharma, lending external credibility to the pipeline.[provided_text]
• Strategic rationale for in-house manufacturing build-out. The in-house manufacturing slide outlines a coherent rationale for building internal capabilities—integrating services and IP protection, reducing reliance on external manufacturers and offering one-stop services—which can appeal to investors seeking margin expansion and strategic control.[provided_text]
• Public-company discipline in disclosure and risk framing. Forward-looking statements and risk language early in the deck reflect public-company discipline and align with regulatory expectations for TSX-V/OTCQX-listed issuers, which can increase investor confidence in governance and disclosure practices.[provided_text]

What could have been stronger

• TAM figures are high-level and not clearly sourced or segmented. Although the deck cites a $19B total addressable market and breaks out $17B for VersaFilm and $1.7B for VersaTab, it does not, based on the extracted text, provide a clear bottoms-up segmentation or specific source references for these TAM figures, making it difficult for investors to assess how much of that opportunity is realistically addressable by IntelGenx’s specific products.[provided_text]
• Limited quantified traction and financial detail in the visible slides. The slides emphasize record Q3 revenue, profitability and “market momentum” with Forfivo XL but the excerpted text does not show concrete numerical financial metrics such as revenue levels, growth percentages, or contribution by product, which would help investors quantify traction.[provided_text]
• Unclear regulatory timelines and risk profile across the pipeline. The deck stresses that two film products are awaiting FDA approval and highlights multiple therapeutic targets (opioid dependence, migraine, erectile dysfunction, schizophrenia), but the extracted content does not specify the exact regulatory stage, timelines or probability of success for each program, which adds uncertainty to the development pipeline.[provided_text]
• Manufacturing strategy benefits are emphasized without matching discussion of capital and execution risks. While IntelGenx’s move to in-house manufacturing is presented as a driver of increased profitability and one-stop service, the deck excerpt does not discuss the associated capital requirements, ramp-up risks or utilization assumptions, even though SEC filings show dependence on a government-backed credit facility and loans to finance the facilities.[provided_text]

How an investor would read this deck

What draws attention

• IntelGenx’s positioning as a specialist in oral thin film and advanced tablet technologies (VersaFilm, VersaTab, AdVersa) that reformulate approved drugs to improve convenience and onset of action.[provided_text]
• The claimed $19B total addressable market, with VersaFilm alone targeting about $17B across migraine, opioid dependence, erectile dysfunction and schizophrenia, offering large-market indications for follow-on products.[provided_text]
• Evidence of commercial traction via Forfivo XL, a high-dose once-daily bupropion XL tablet for depression launched in partnership with Edgemont Pharmaceuticals, which IntelGenx highlights as having growing net sales by late 2015.
• Regulatory and commercial validation from European marketing approval for RIZAPORT and subsequent distribution agreements in Spain and South Korea with partners such as RedHill Biopharma and Grupo Juste/Exeltis.[provided_text]
• The transition to in-house manufacturing capabilities, backed by government-supported credit facilities and loans, which could improve margins and control over production in the medium term.[provided_text]

Risks that stand out

• Reliance on reformulations of existing drugs in crowded markets such as antidepressants, migraine and erectile dysfunction, which may face strong competition from generics and other delivery forms despite IntelGenx’s convenience advantages.
• Regulatory risk associated with dependence on FDA and other regulatory approvals for multiple oral film and tablet products; the deck’s reference to two film products awaiting FDA approval underscores exposure to potential delays or non-approvals.[provided_text]
• Dependency on external partners for commercialization (e.g., Edgemont for Forfivo XL, RedHill and regional distributors for RIZAPORT), creating counterparty risk and limiting IntelGenx’s control over marketing and sales outcomes.
• Execution and financial risk from the capital-intensive move to in-house manufacturing, including the need to service government-backed debt and achieve sufficient production volume to realize the projected profitability benefits.
• Potential dilution or financing risk, given IntelGenx’s history of public offerings and need to fund R&D, manufacturing expansion and regulatory processes in an environment where product approvals and sales ramp-ups may be uncertain.

Questions this deck invites

• How exactly is the $17B VersaFilm and $1.7B VersaTab total addressable market calculated, and what share of each indication (migraine, opioid dependence, erectile dysfunction, schizophrenia) is realistically accessible to IntelGenx’s specif
• What were IntelGenx’s detailed financial metrics around 2014–2016 (product-level revenue, Forfivo XL royalty streams, operating margin, R&D spend), and how do these compare to the “record Q3 revenue and profitability” claims in the deck?
• For each of the two oral film products that the deck states are awaiting FDA approval, what is the regulatory history (complete response letters, additional trials, partnerships) and current status, including any approvals, delays or discon
• How has the in-house manufacturing facility performed since commissioning (capacity utilization, COGS impact, ability to attract CDMO clients), and what covenants or terms apply to the BMO and Investissement Québec financings used to build
• What are the key partnership terms with RedHill Biopharma, Edgemont Pharmaceuticals and other partners (upfronts, milestones, royalty rates, co-funding obligations), and how sensitive is IntelGenx’s business model to the performance and str

What founders can take from the IntelGenx Corp. deck

• Specializing in a specific drug delivery modality, such as oral thin films (VersaFilm), can provide a clear and differentiated narrative when the deck connects the technology to tangible patient benefits like rapid disintegration, faster onset and easier administration for populations that struggle
• Reframing the business around “making approved drugs better” helps investors quickly understand that the company’s strategy is lifecycle management and reformulation rather than de novo drug discovery, which can imply lower scientific risk and shorter timelines.[provided_text]
• Anchoring a deck around a single flagship platform (VersaFilm) while clearly naming complementary platforms (VersaTab, AdVersa) can show both focus and optionality, particularly when each is aligned to large, well-known therapeutic markets.[provided_text]
• Highlighting concrete external validations—such as European marketing approval for RIZAPORT and a commercial launch of Forfivo XL with a partner—adds credibility beyond projections and underscores that the technology has passed regulatory and commercial hurdles.[provided_text]
• Linking a manufacturing strategy to financial outcomes (e.g., increased profitability, IP protection, one-stop services) can strengthen the story, but investor decks benefit from pairing these claims with transparent discussion of financing sources and capital intensity, as seen by IntelGenx’s discl
• Using a large TAM figure (like $19B) can attract attention, but investors will scrutinize how well the deck breaks that down into specific indications and addressable segments, highlighting the importance of clearly backing TAM claims with segmentation and external data.[provided_text]

IntelGenx Corp. pitch deck: common questions

What does IntelGenx Corp. do?

IntelGenx is a specialty pharmaceutical company that develops oral drug delivery systems such as oral thin films (VersaFilm), multilayer tablets (VersaTab) and mucoadhesive tablets (AdVersa) to reformulate existing drugs and co-develop new products with partners.

What kind of fundraising stage was IntelGenx in for this deck?

The deck is a January 2016 investor presentation used while IntelGenx was already publicly traded on the TSX Venture Exchange (IGX) and OTCQX (IGXT), focusing on its VersaFilm oral thin film platform, Forfivo XL commercialization and RIZAPORT approval, rather than a classic private funding round.

What market opportunity does the 2016 IntelGenx deck claim?

The deck highlights a $19B total addressable market, with approximately $17B attributed to VersaFilm oral thin films (including migraine, opioid dependence, erectile dysfunction and schizophrenia indications) and about $1.7B for VersaTab multilayer tablets.[provided_text]

Did IntelGenx raise a specific round linked to this January 2016 deck?

IntelGenx’s publicly disclosed financing around this period includes earlier offerings, such as a December 2013 registered public offering that raised gross proceeds of approximately $3.5 million for VersaFilm manufacturing equipment and a new facility, and debt financing for a new manufacturing facility financed via a government-backed bank credit facility of up to CAD$3.5 million with BMO Bank of Montreal and a CAD$1 million loan from Investissement Québec, as described in its 2015 Form 10-K. There is no specific public record tying the January 2016 deck to a distinct equity round with a disclosed size or lead investor.

What is RIZAPORT and what status did it have around this deck?

RIZAPORT is IntelGenx’s proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines, developed using its VersaFilm technology. The deck notes it had achieved its first European marketing approval for RIZAPORT by that time, and later disclosures show IntelGenx and its partner RedHill Biopharma securing distribution agreements for RIZAPORT in Spain and South Korea in 2016.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• Igx investor presentation jan 14, 2016
• Igx investor presentation jan 13, 2016
• Intelgenx may 20 2016 | PDF
• Intelgenx april 7-2016
• IntelGenx Corp. - Exhibit 99.1 - Filed by newsfilecorp.com - SEC.gov
• IntelGenx Technologies Corp. (Form: 10-K, Received
• Intelgenx Investor Presentation - July 6 2016
• IGX Investor Presentation | PDF - Slideshare

IntelGenx Corp. pitch deck slides

What each slide of the IntelGenx Corp. pitch deck says

Slide 1

IntelGen y Corp. Innovative Drug Delivery Solutions We Make Approved Drugs Better January 13, 2016 TSX-V: IGX OTCQX: IGXT

Slide 2

Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar express…

Slide 3

IntelGen y Corp. Oral Thin Films Provide Significant Market Opportunities for Improving Drug Delivery IGX CEO co-developer of the Listerine breath strips Oral films ideal for elderly, children, patients who have difficulty swallowing traditional tablets Quicker action to relieve symptoms

Slide 4

Making Approved Drugs Better Through Innovative Drug Delivery Solutions IntelGenx develops and manufactures faster and more efficient drug delivery systems for top pharmaceuticals IntelGenx Drug Delivery Technology Platforms Films Tablets Controlled-release tablets for oral Rapidly disintegrating film improving ) ) ) absorption over an extended time period drug performance and easing administration without the need for water VersaFilm™ VersaTab™ AdVersa™ Rizaport™ IntelGen y Corp.

Slide 5

Investment Highlights - Developing proprietary oral drug delivery technologies to address $19B TAM - Market momentum with Forfivo XL @ tablets - Achieved first European marketing approval of RIZAPORT™ for Migraines - Robust product pipeline to enable expansion into other market segments with significant TAM - Achieved record Q3 revenue and profitability IntelGeny Corp. VersaFilm™ $17B TAM VersaTab™ $1.7B TAM

Slide 6

FORFIVO XL® — First 450mg tablet approved by = FDA for major depressive disorder + High dose version of Wellbutrin XL® FORFIVO XL® NET SALES ($Thousands) - Only approved, once-daily, bupropion FE HCI 450mg dose in a single tablet $2,500 + Launched commercially October 2013 in $2,132 partnership with Edgemont oor $1756 peat Pharmaceuticals ’ $1,697 iia + Q3 2015 net sales grew 16% compared to $1,195 a Q2 2015, with net sales at $2.5 million A ($4.7 million gross) - vert? - For the past nine months, net sales totaled $6.3 million ($12 million gross), an increase of 117% compared to the nine month period in 2014 5 3014 4Q14 1Q15 2015 3015 IntelGen y Corp.

Slide 7

VersaFilm™ Oral Thin Films Drug Delivery Technology Over $17B Market Opportunity and Growth Platform for IGX Benefits of VersaFilm™ - Improves patients compliance who have OPIOD DEPENDENCE MIGRAINE problems swallowing tablets and capsules to Targeted Suboxone Targeted Rizatriptan more easily take medication Sales Market - Rapid disintegration without the need for water $1 .7B $2B - Improves absorption — faster onset of action + Potential for reduced adverse effects ERECTILE SCHIZOPHRENIA DYSFUNCTION $17B Addressable Market Targeted Sales Targeted Cialis® - Successful pivotal bioequivalence studies $5.ZB Sales + Two film products awaiting FDA approval $4-ZB + Limited number of competitors In…

Slide 11

In-House Manufacturing Approach Full Manufacturing Capabilities Establishing manufacturing capability to increase profitability v Integrate pharmaceutical services and IP protection v Reduce dependence by IntelGenx on external manufacturing partners v Offer clients the advantage to obtain all services from one source ("one-stop shopping") v Increase R&D capabilities with expanded laboratories and technologies IntelGen y Corp. Blending Coating Packaging

Slide text above is read directly from the IntelGenx Corp. deck PDF embedded on this page.

Related fundraising guides (24)

• Layla Pitch Deck Teardown: A $3M Seed Round Built on AI-Powered Travel Discovery
• Curio.io Pitch Deck Teardown: Selling High-Engagement Audio Journalism
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Alcatraz AI Pitch Deck Teardown: Leveraging Apple FaceID Pedigree for Enterprise Security
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• CMR Surgical Pitch Deck Teardown: A $600M Masterclass in Ecosystem-Led Medical Robotics
• Depict.ai Pitch Deck Teardown: A Masterclass in Traction-First Seed Fundraising
• Evy Pitch Deck Teardown: A 10-Slide Masterclass in Embedded Insurance Minimalism
• Handly Pitch Deck Teardown: A B2B2C Play for the €5 Trillion Craft Services Market
• Hopscotch Pitch Deck Teardown: A $8M Seed Round for Pediatric Behavioral Health Infrastructure
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization
• Avo Pitch Deck Teardown: A B2B2C Strategy for Last-Mile Logistics Dominance
• CAMP4 Therapeutics Pitch Deck Teardown: A $100M Masterclass in Biotech Platform Validation
• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• EcoLocked Pitch Deck Teardown: Decarbonizing Construction via Biochar Admixes
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• Hang Pitch Deck Teardown: A $16M Series A Masterclass in Web3 Enterprise Utility
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• Thematic Pitch Deck Teardown: Leveraging Creator Networks for Scalable Music Promotion

Decks from the same year (1)

• 2016 pitch deck examples

Decks from the same region (1)

• Canadian pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with I

More pitch deck teardowns (16)

• Intact Financial Corporation Pitch Deck Teardown: A Public Market Investor Relations Case Study
• IFG Technology Pitch Deck Teardown: A High-Level Cybersecurity Services Framework
• Ignilife Pitch Deck Teardown: A Minimalist B2B2C Health Platform Strategy
• Ignite! Reading Pitch Deck Teardown: A $10M Series A Built on Efficacy and Policy Tailwinds
• Ignota Labs Pitch Deck Teardown: Reviving Abandoned Drug Assets via AI Safety Diagnostics
• iGrow Pitch Deck Breakdown: Scaling Indonesian AgTech Through Fractional Investment
• IGT Financial Services Pitch Deck Teardown: A Blueprint for Rural Microfinance in India
• IntelGenx Corp. Pitch Deck Teardown: Leveraging Oral Thin Film Tech for a $19B TAM
• Illumen Capital Pitch Deck Breakdown: A $168M Fund of Funds Strategy for Bias Reduction
• iLobby Pitch Deck Breakdown: Dominating Enterprise Visitor Management via Compliance
• Imago Pitch Deck Teardown: Visualizing Geoscientific Data for the Mining Sector
• IMAN Pitch Deck Teardown: Building a Sharia-Compliant BNPL Ecosystem in Frontier Markets
• IMAX of Gaming Cafe Pitch Deck Teardown: A High-Concept Play for India's Tech Professionals
• ImBlaze Pitch Deck Teardown: Solving the 10-Hour Internship Logistics Problem
• VRoom Pitch Deck Teardown: The 2016 Quest for a Unified Virtual Reality Business Platform
• Immo Pitch Deck Breakdown: Institutionalizing European Residential Real Estate

Recently published pitch deck teardowns (12)

• Fungible Pitch Deck Breakdown: A $310M Vision for the Data Processing Unit
• Fynd Pitch Deck Breakdown: Scaling O2O Fashion Retail via Real-Time Inventory
• Gearflow Pitch Deck Breakdown: Solving Construction Downtime with a Niche Marketplace
• gazeMetrix Pitch Deck Breakdown: Visualizing Brand Mentions with Computer Vision
• Geodesic.Life Pitch Deck Breakdown: Solving Rural Housing with Prefabricated Domes
• Get on Board Pitch Deck Breakdown: Leveraging Data to Unify the Latin American Tech Market
• GRUBBRR Pitch Deck Breakdown: Replacing the Cashier with Enterprise Automation
• Hangry Pitch Deck Breakdown: Scaling Multi-Brand Virtual Restaurants in Indonesia
• Hearo.live Pitch Deck Breakdown: A 9-Slide Bet on Multiplayer Media
• Hims & Hers Pitch Deck Breakdown: Scaling Telehealth Through Vertical Integration
• Heyday Pitch Deck Breakdown: A $2M Seed Round for Conversational AI in Retail
• Iconfinder Pitch Deck Breakdown: Scaling a Search Engine into a Global Marketplace

Fundraising library · Pitch deck examples · Investor directory · Founder database